Leukemia, B-cell
25
4
5
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
8.0%
2 terminated out of 25 trials
33.3%
-53.2% vs benchmark
8%
2 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (25)
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
Precision Exercise in Children With Malignant Hemopathies
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
CAR-T Cells in the Treatment of Malignant Hematological Tumors
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL